The present invention relates to the use of at least one protease for themanufacture of a medicament for the treatmentand/ or prevention of benign prostate hypertrophy/hyperplasia, wherein themedicament is adapted for enteral administration, the atleast one protease is selected from the group consisting of plant, non-mammalian animal and microbial proteases and the at least oneprotease is administered in an amount of 1 to 100 mg/kg body weight.
